Evidence map›Paper›PMID 38573936›Full record

ArticlePloS one2024

AI technology specialization and national competitiveness.

Youngsam Chun, Jisoo Hur, Junseok Hwang

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Youngsam ChunTechnology Management, Economics and Policy Program (TEMEP), Seoul National University, Gwanak-gu, Seoul, South Korea.ORCID 0000-0002-6877-6230
Jisoo HurTechnology Management, Economics and Policy Program (TEMEP), Seoul National University, Gwanak-gu, Seoul, South Korea.ORCID 0009-0004-1031-8036
Junseok HwangTechnology Management, Economics and Policy Program (TEMEP), Seoul National University, Gwanak-gu, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the factors influencing specialization in artificial intelligence (AI) technology, a critical element of national competitiveness. We utilized a revealed comparative advantage matrix to evaluate technological specialization across countries and employed a three-way fixed-effect panel logit model to examine the relationship between AI specialization and its determinants. The results indicate that the development of AI technology is strongly contingent on a nation's pre-existing technological capabilities, which significantly affect AI specialization in emerging domains. Additionally, this study reveals that scientific knowledge has a positive impact on technological specialization, highlighting the necessity of integrating scientific advancements with technological sectors. Although complex technologies positively influence AI specialization, their effect is less pronounced than that of scientific knowledge. This suggests that in rapidly advancing fields, such as AI, incorporating new scientific knowledge into related industries may be more advantageous than simply advancing existing technologies to outpace competitors. This insight points nations toward enhancing AI competitiveness in new areas, emphasizing the vital importance of both scientific and technological capabilities, and the integration of novel AI knowledge with established sectors. This research offers critical guidance for policymakers in less technologically and economically developed countries, as these nations may not have the technological infrastructure required to foster AI specialization through increased technical complexity.

Indexed as

Artificial IntelligenceIndustryKnowledgeLogistic ModelsTechnology

Identifiers

PMID38573936
PMCPMC10994314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.